SALIVARY GLAND TUMORS - A SEVEN YEARS STUDY AT ARMED FORCES INSTITUTE OF PATHOLOGY RAWALPINDI, PAKISTAN
Abstract
Objective: To compare the frequency of benign and malignant tumors in the salivary gland.
Material & Methods: This Retrospective study was carried out at Histopathology Department, Armed Forces Institute of Pathology (AFIP) Rawalpindi, over a period of 7 years (Jan 2010 to 31st Dec 2016) including a total of sixty (n=60) major and minor salivary gland tumor cases, accessioned from 1st Jan 2010 to 31st Dec 2016. Descriptive statistics and frequencies were calculated with respect to age, gender, anatomical location and histopathological type. The data was analyzed using SPSS version 24.
Results: A total of 60 cases were included, out of which 29 were of male patients while 31 were of female patients. They were within the age range of 3 to 88 years. Mean age being 44.01 + 17.71 years. Benign tumors were more frequent (51.66%) than malignant (48.33%). The commonest anatomical site for benign tumor was parotid gland (54.84%), whereas for the malignant tumors it was submandibular gland (75.86%). Pleomorphic adenoma was found to be the most common benign tumor in both genders (93.75%, n=15 in females, 93.33% n=14 in males). Among the malignant tumors, the commonest one in the males was found to be mucoepidermoid carcinoma (42.9% n=6) which in turn was followed by adenoid cystic carcinoma and epithelial and myoepithelial carcinoma (14.3% each n=2). In the females, adenoid cystic carcinoma was the most prevalent tumor (46.7% n=7) followed by mucoepidermoid carcinoma (20% n=3). Benign tumor had a peak incidence at 51-60 years of age followed by 21-30 years. Whereas the malignant tumors, were the most prevalent within the age group of 61-70 years followed by 41-51 years.
Key Words: Adenoid cystic carcinoma, Pleomorphic adenoma, Salivary gland tumors.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Muhammad Asif, Sheza Malik, Ayesha Khalid, Madeeha Anwar, Hafeez Ud Din, Muhammad Tahir Khadim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.